Magnetic drug-targeting carrier encapsulated with thermosensitive smart polymer: Core–shell nanoparticle carrier and drug release response

2007 ◽  
Vol 3 (6) ◽  
pp. 838-850 ◽  
Author(s):  
J. Zhang ◽  
R.D.K. Misra
2015 ◽  
Vol 380 ◽  
pp. 285-294 ◽  
Author(s):  
Prabu Chakkarapani ◽  
Latha Subbiah ◽  
Selvamani Palanisamy ◽  
Arputha Bibiana ◽  
Fredrik Ahrentorp ◽  
...  

2019 ◽  
Vol 5 (1) ◽  
pp. 161-164 ◽  
Author(s):  
Diana Zahn ◽  
Andreas Weidner ◽  
Katayoun Saatchi ◽  
Urs O. Häfeli ◽  
Silvio Dutz

AbstractMagnetic microspheres (MMS) used for magnetic drug targeting consist of magnetic nanoparticles (MNP) and a pharmaceutical agent embedded in a polymeric matrix material. The application of MNP for drug targeting enables guiding the MMS to a target area, imaging the position of the MMS with magnetic particle imaging, and finally inducing drug release. As latter takes place by degradation of the MMS or diffusion through the matrix, an increase in temperature, e.g. through magnetic hyperthermia, leads to an accelerated drug release. Here, MMS consisting of poly(lactic-coglycolic) acid (PLGA) with different monomer ratios were prepared by an oil-in-water emulsion evaporation method. The model drug Camptothecin (CPT) and magnetic multicore nanoparticles (MCNP) with a high specific heating rate were embedded into the microspheres. We obtained MMS in the preferred size range of 1 to 2 μm with a concentration of MCNP of 16wt%, a drug load of about 0.5wt% and an excellent heating performance of 161 W/gMMS. Investigations of the drug release behaviour showed an accelerated drug release when increasing the temperature from 20 °C to 37 °C or 43 °C by using a water bath. In addition, an increase in drug release of about 50% through magnetic heating of the MMS up to 44 °C compared to 37 °C was observed. By this, a magnetic hyperthermia induced CPT release from PLGA MMS is demonstrated for the very first time.


2019 ◽  
Vol 9 (01) ◽  
pp. 58-64
Author(s):  
Senthilnathan B ◽  
Billy Graham R ◽  
Chaarmila Sherin C ◽  
Vivekanandan K ◽  
Bhavya E

Objective: Drug targeting is the capacity of the dosage form. In which the therapeutic agent acts specifically to desired site of action in the non-targeted tissue with the help of Nano particles is called as the drug targeting. IMATINIB is a used to treat cancer by chemo therapy. Cancers like chronic myeloid leukemia cancer (CML) and acute lymphoblastic leukemia cancer (ALL) and other specific types of gastrointestinal stromal cell tumor (GIST) systemic mast cell disease and Bone marrow failure disorder. It is administered by oral root. For ATP, Tyrosine kinase is act as a binding site. Methodology: The drug IMATINIB is loaded in the polymer chitosan, poly-(D) glucosamine is a bio compactible, bio degradable, nontoxic, antimicrobial and soluble in solvents. This preparation is done by emulsion-droplet coalescence method. Content of the Drug, Size of the particle and Zeta potential, Encapsulation efficiency and Drug release testing are described for this formulation in this study. Results: The Imatinib Nano particles were formulated and evaluated for its invitro drug release profile. Based on the invitro drug release profile of Imatinib nano particles formulation (INP1 – INP5) formulation INP3 was selected as the best formulation in which the particle size was 285.9nm. The invitro % drug release of INP3 formulation was 99.76 ± 0.82 and it was found to be the suitable formulation to manage the cancer. Conclusion: Hence it is concluded that the newly formulated controlled release nanoparticle drug delivery system of Imatinib may be idol and effective by allowing the drug to release continuously for 24 hrs.


Nanomaterials ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 1546
Author(s):  
Zhen Li ◽  
Shunqi Mei ◽  
Yajie Dong ◽  
Fenghua She ◽  
Puwang Li ◽  
...  

Core-shell nanofibers have great potential for bio-medical applications such as wound healing dressings where multiple drugs and growth factors are expected to be delivered at different healing phases. Compared to monoaxial nanofibers, core-shell nanofibers can control the drug release profile easier, providing sustainable and effective drugs and growth factors for wound healing. However, it is challenging to produce core-shell structured nanofibers with a high production rate at low energy consumption. Co-axial centrifugal spinning is an alternative method to address the above limitations to produce core-shell nanofibers effectively. In this study, a co-axial centrifugal spinning device was designed and assembled to produce core-shell nanofibers for controlling the release rate of ibuprofen and hEGF in inflammation and proliferation phases during the wound healing process. Core-shell structured nanofibers were confirmed by TEM. This work demonstrated that the co-axial centrifugal spinning is a high productivity process that can produce materials with a 3D environment mimicking natural tissue scaffold, and the specific drug can be loaded into different layers to control the drug release rate to improve the drug efficiency and promote wound healing.


ACS Nano ◽  
2012 ◽  
Vol 6 (4) ◽  
pp. 3327-3338 ◽  
Author(s):  
Yunlu Dai ◽  
Ping’an Ma ◽  
Ziyong Cheng ◽  
Xiaojiao Kang ◽  
Xiao Zhang ◽  
...  

2020 ◽  
Vol 6 (3) ◽  
pp. 543-546
Author(s):  
Michael Fink ◽  
Stefan J. Rupitsch ◽  
Helmut Ermert ◽  
Stefan Lyer

AbstractVarious medical procedures make use of magnetic nanoparticles, such as Magnetic Drug Targeting (MDT), which boosts the demand for imaging modalities that are capable of in vivo visualizing this kind of particles. Magnetomotive Ultrasound is an imaging technique that can detect tissue, which is perfused by magnetic nanoparticles. In this contribution, we investigate the suitability of Magnetomotive Ultrasound to serve as a monitoring system during MDT. With the conducted measurements, it was possible for the first time to observe in vivo the accumulation of iron-oxide nanoparticles during a Magnetic Drug Targeting cancer treatment applied to a small animal (rabbit).


2013 ◽  
Vol 9 (7) ◽  
pp. 7410-7419 ◽  
Author(s):  
Jun Wu ◽  
Tiantian Kong ◽  
Kelvin Wai Kwok Yeung ◽  
Ho Cheung Shum ◽  
Kenneth Man Chee Cheung ◽  
...  

RSC Advances ◽  
2021 ◽  
Vol 11 (48) ◽  
pp. 29986-29996
Author(s):  
Xiuxiu Qi ◽  
Hongmei Yan ◽  
Yingxue Li

A pH-sensitive core–shell nanoparticle (HMS@C18@PSDMA-b-POEGMA) was developed via a self-assembly process as the carrier of anticancer drug doxorubicin (DOX) for drug loading and controlled release.


Sign in / Sign up

Export Citation Format

Share Document